www.drugdevelopment-technology.com
News, views and contacts from the global Drugdevelopment industry
26 February 2017
WEEKLY UPDATE
Digital Magazine
Latest Companies

Sartorius - Biopharmaceutical Laboratory Equipment and Integrated Bioprocess Services

Pharmatest Services - Research Models to Evaluate Drug Candidate Efficacy

ImmunoPrecise Antibodies - Custom Monoclonal and Polyclonal Antibody Development

Softigel - Contract Development Services and Drug Delivery Systems

Gamlen Instruments - Benchtop Tablet Manufacture Instruments, Research Analysers, and Formulation Training for Drug Development

Press Releases

Malvern to Host Webinar on Characterisation and Optimisation of Particle Size and Shape of Metal Powders
Efficiency of the production process of powder bed additives is reliant on packing density and flow behaviour of metal powders involved.

Malvern to Unveil New Protein Stability Analysis Device
Malvern has announced it will be unveiling its new protein stability characterisation product for regulated environments MicroCal PEAQ-DSC in an upcoming webinar.

Understanding Particle Size Analysis Webinar
Malvern has announced that it will be presenting a webinar on the basic principles of particle size analysis.

SYSTAG Accelerates OEM Product Development and Software Services
Based in Switzerland, SYSTAG System Technik is accelerating its original equipment manufacturer (OEM) product development, software engineering, and software services, in addition to its own products in automated laboratory reactors and thermal process safety.

Gaining an Understanding of Pharmacokinetic Protocols
Engaged in pharmaceutical consulting, the scientists and regulatory professionals at PDG® are tasked with design of pharmacokinetic (PK) protocols for a wide variety of applications.

White Papers

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture
Systag Systems presents ePAT, a cost-effective device for automation in the laboratory....

How Investing in Malvern Instruments Helped KBI Biopharma Find a Clear Commercial Advantage
Differing sample matrices and presentation can create various challenges, not least for KBI's technology platforms, which often require specialised methods and application experts in order...

Optimising Development Resources for Efficient Product Development
Development departments suffer from a shortage of resources and are often overburdened with administration...

GPC/SEC Analysis of Polymer Solutions Used in Inkjet Printing
Inkjet printing of polymer solutions is an area of interest for depositing precise, high-throughput patterns of functional polymer. The applications of the polymer patterns include OLEDs,...

Gold Nanoparticle Applications and Characterization by Nanoparticle Tracking Analysis
Gold nanoparticles are one of the most popular and extensively researched type of nanoparticle. A Google Scholar search of the term 'gold nanoparticles' results in more than 500,000...

Features

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopment-technology.com wraps-up the key headlines from January.

2016: The year's biggest Drug Development Technology stories
NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016.

November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial
UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November.

October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child
Eurocine Vaccines initiated a Phase I/II influenza vaccine study and a new study suggested in-vitro fertilisation increases the chances of conceiving a male child. Drugdevelopment-technology.com wraps up the key headlines from October 2016.

September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada
Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat post-traumatic stress disorder. Drugdevelopment-technology.com wraps up the key headlines from September 2016.

Projects

Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy
Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals.

Symbicort (budesonide and formoterol) for the Treatment of Asthma
Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZeneca.

Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC)
Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC).

Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Avelumab (formerly MSB0010718C) is a human PD-L1 monoclonal antibody being investigated for the treatment of metastatic Merkel cell carcinoma (MCC).

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA)
Spinraza™ (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.